Join our email list for exclusive offers! OFF! 👏

YK-11 Powder | 1 Gram

 Selling fast! Get yours today  Same-day shipping available

$89.99

In stock

Description

Research-Grade Steroidal SARM Reference Material

YK-11 Powder — 1 Gram

YK-11 is a synthetic steroidal compound, derived from 5α-dihydrotestosterone (DHT), that has been characterized in cell studies as a partial agonist of the androgen receptor. Although it is commonly grouped with SARMs, its steroid backbone distinguishes it structurally from non-steroidal SARMs such as ostarine or ligandrol. This listing is a research-grade reference compound supplied in powder form for in vitro and laboratory investigation. Identity and purity are third-party verified and documented by a batch-dated, downloadable Certificate of Analysis.

  • 98.76% purity (HPLC)
  • Third-party verified
  • 1,050 mg net
  • Batch-dated COA
  • UV-resistant foil pouch
Technical Reference

Specifications & Documentation

Compound
YK-11 (YK11)
Chemical Name
(17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester
CAS Number
1370003-76-1
Molecular Formula
C₂₅H₃₄O₆
Molar Mass
430.54 g/mol
Compound Class
Steroidal androgen receptor partial agonist (commonly grouped with SARMs)
WADA Classification
Prohibited — Class S1.2 (Other Anabolic Agents)
Form
Crystalline powder
Net Quantity
1,050 mg per pouch
Verified Purity
98.76% by HPLC (COA dated 09/03/2025)
Why Verification Matters

Quality & Analytical Transparency

Independent analysis has repeatedly found that materials sold online as SARMs are frequently mislabeled or adulterated. A 2017 JAMA investigation that chemically analyzed products marketed as SARMs found that only a minority accurately matched their labeled contents, and a substantial share contained unapproved or entirely different substances.[6] Third-party testing is the control that distinguishes a documented reference compound from an unverified one.

98.76%HPLC Purity
HPLCPurity Method
MSIdentity Confirmation
GLPTesting Standard
Scientific Background

Research Context

YK-11 was first described in 2011 by Japanese researchers as a partial agonist of the androgen receptor with gene-selective activity in MDA-MB-453 cells.[1] Subsequent cell studies reported that it induced follistatin expression during myogenic differentiation of C2C12 myoblasts[2] and influenced proliferation and differentiation markers in MC3T3-E1 osteoblastic cells.[3] It has also been examined in a mouse model of bacterial sepsis.[4] A 2024 rat study reported that YK-11 reached the hippocampus and was associated with increased pro-inflammatory cytokines, activation of apoptotic signaling, and altered memory consolidation.[5] Most published data on YK-11 come from cell culture, and its effects and safety in humans have not been established.

This material is supplied strictly as a reference compound to support such laboratory investigation. It is not a therapeutic product, dietary supplement, or sports supplement, and no clinical or performance outcomes are claimed or implied for any individual.

Regulatory Status

Compliance & Legal Status

YK-11 is an investigational compound that has not been approved by the U.S. Food and Drug Administration for human use. It is not a dietary supplement, and marketing it for human ingestion is unlawful. It is supplied exclusively for laboratory research purposes.

FDA StatusNot approved for human use; not a dietary or sports supplement.
WADA StatusProhibited at all times — Class S1.2, Other Anabolic Agents.[7]
Intended UseLaboratory / in vitro research reference material only.
Not ForHuman or animal consumption, diagnosis, treatment, or performance use.
Citations

Scientific References

  1. Kanno Y, Hikosaka R, Zhang SY, et al. (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor. Biol Pharm Bull. 2011;34(3):318–323.
  2. Kanno Y, Ota R, Someya K, et al. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. Biol Pharm Bull. 2013;36(9):1460–1465.
  3. Yatsu T, Kusakabe T, Kato K, et al. Selective androgen receptor modulator, YK11, up-regulates osteoblastic proliferation and differentiation in MC3T3-E1 cells. Biol Pharm Bull. 2018;41(3):394–398.
  4. Lee SJ, Gharbi A, Shin JE, et al. Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis. Biochem Biophys Res Commun. 2021;543:1–7.
  5. From gains to gaps? How selective androgen receptor modulator (SARM) YK11 impact hippocampal function: in silico, in vivo, and ex vivo perspectives. Chem Biol Interact. 2024;394:110971.
  6. Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 2017;318(20):2004–2010.
  7. World Anti-Doping Agency. The Prohibited List, Section S1.2: Other Anabolic Agents. WADA.org.

Research Disclaimer

For laboratory research use only. This preparation is not approved by the FDA for human use. YK-11 is not a dietary or sports supplement and is not intended for human or animal consumption.

All products on this website are intended exclusively for research and development purposes. The statements herein have not been evaluated by the U.S. Food and Drug Administration. Neither the statements nor the products are intended to diagnose, treat, cure, or prevent any disease. Sports Technology Labs are chemical suppliers, not medical practitioners; our expertise is sourcing and quality control.

Additional information

Weight 2 oz
Dimensions 3 × 0.3 × 4 in

Related Products